Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: Roche - Prof. Dr. Jens Huober et al.
• Treatments: Letrozole; Trastuzumab

Criteria

Inclusion Criteria:

• Postmenopausal

• Her-2 overexpression and ER and/or PgR positive

• Metastatic Breast Cancer

Exclusion Criteria:

• Previous treatment with trastuzumab

• Significant Liver or renal impairment

• Erbb2 negative and/or ER and PgR negative

Other protocol-defined inclusion / exclusion criteria may apply.